|
Day 2: 13 October 2018
|
|
8.30am to 9am
|
Registration
|
|
9am to 10am
|
Session 3: Tumor Antigens and Cancer Vaccines
Moderators:
Dr. Reyad Mohsen, MD FACP - Senior Consultant, Medical Oncology, National Center for Cancer Care and Research, Hamad Medical Corporation
Prof. Martin Steinhoff - Senior Consultant, Director of Dermatology Department, Rumailah Hospital and Director of interim Translational Research Institute, Academic Health System, Hamad
Medical Corporation
|
|
9am to 9.30am
|
Immunovirotherapy: Targeted In Situ Vaccination
Prof. Guy Ungerechts, MD. PhD.
Deputy Director
Medical Oncology Department
National Center for Tumor Diseases (NCT)
University Hospital Heidelberg
Im Neuenheimer Feld 460
Heidelberg, Germany
|
|
9.30am to 10am
|
Potential Target Antigens for Specific Immunotherapy of Head and Neck Cancer
PD Dr.Med. Simon Laban
Head of the Clinical Trials Unit for Head & Neck Cancer and Coordinator of the Head & Neck Cancer Center of the CCCU
Comprehensive Cancer Center Ulm (CCCU)
University Medical Center Ulm
Department of Otorhinolaryngology and Head & Neck Surgery
Ulm, Germany
|
|
10am to 10.30 am
|
Coffee Break; Posters
|
|
10.30am to 11.30am
|
Session 4: Immune Checkpoint Inhibitors and Immune-Regulation
Moderators:
Dr. Salha Bujassoum - Senior Consultant, Medical Oncology, National Center for Cancer Care and Research, Hamad Medical Corporation
Dr. Anas Hamad - Director of Pharmacy, National Center for Cancer Care and Research, Hamad Medical Corporation
|
|
10.30am to 11am
|
Immunosuppression in Cancer: T regulatory cells, Immune Checkpoints and More
Dr. Eyad Elkord, PhD.
Senior Scientist
Qatar Biomedical Research Institute
Associate Professor
Hamad Bin Khalifa University
Doha Qatar
|
|
11am to 11.30am
|
Factors Contributing to Response and Resistance to Immune Checkpoint Blockade
Dr. Taha Merghoub, PhD
Co-Director of the Ludwig Collaborative Laboratory
Memorial Sloan Kettering Cancer Center
New York, USA
|
|
11.30am to 1pm
|
Prayer and Lunch Break; Posters
|
|
1pm to 2.30pm
|
Session 5: Cancer Vaccine Design
Moderators:
Dr. Ussama Al Homsi - Senior Consultant Oncology and Chairman of the Hematology & Oncology, National Center for Cancer Care and Research, Hamad Medical Corporation
Dr. Gianfranco Pittari - Senior Consultant Hematology, National Center for Cancer Care and Research, Hamad Medical Corporation
|
|
1pm to 1.30pm
|
Developing Personalized Cancer Vaccines: Strategic Challenges and Potential Solutions
Prof. Martin Bachmann, PhD.
Professor of Immunology
University of Bern and University of Oxford
Oxford, UK
|
|
1.30pm to 2pm
|
VLPs for Vaccine Development
Dr. Mona Omar Mohsen, PhD.
Post Doctoral Fellow, Qatar Research Leadership Program
The Jenner Institute
Nuffield Department of Medicine
University of Oxford
Oxford, UK
|
|
2pm to 2.30pm
|
Cancer Testis Antigen Vaccines: Lessons Learned From MAGE-A3 and NY-ESO-1
Dr. Julie Decock, PhD.
Scientist
Qatar Biomedical Research Institute
Assistant Professor, College of Science and Engineering
Hamad Bin Khalifa University
Doha, Qatar
|
|
2.30pm to
2.50pm
|
Coffee Break
|
|
2.50pm to
5pm
|
Session 6: Biomarkers and Cancer Immunotherapy
Moderators:
Dr. Ahmad Al-Sabbagh - Senior Consultant, Head of Hematopathology Division, Department of Laboratory Medicine and Pathology, Laboratory Director, National Centre for Cancer Care and Research, Hamad Medical Corporation
Dr. Mohamed Ben-Gashir - Consultant, Clinical Laboratory, Department of Laboratory Medicine and Pathology, Hamad Medical Corporation
|
|
2.50pm to 3.20pm
|
Immune Profiling of Cancer Patients Undergoing Immunotherapy Treatments: Advances and Challenges
Dr. Cristina Maccalli, PhD.
Staff Scientist
Clinical Research Center, Division of Translational Medicine
Sidra Medicine
Doha, Qatar
|
|
3.20pm to 3.50pm
|
Harnessing the Prognostic and Predictive Potential of Lymphoid Neogenesis in Cancer
Dr. Karina Silina, PhD.
Post Doctoral Fellow
Institute of Experimental Immunology
University of Zurich
Zurich, Switzerland
|
|
3.50pm to 4.20pm
|
Differential Expression of Immunological Markers After Immune Checkpoint Inhibition
Dr. Said Dermime, PhD.
Senior Scientist
Director of Translational Cancer Research Facility
National Center for Cancer Care and Research
Hamad Medical Corporation
Doha, Qatar
|
|
4.20pm to 4.50pm
|
Restoring Natural Killer Cell Immunity Against Multiple Myeloma in the Era of New Drugs
Dr. Gianfranco Pittari, MD, PhD.
Senior Consultant
National Center for Cancer Care and Research
Hamad Medical Corporation
Doha, Qatar
|
|
4.50pm to
5pm
|
Closing Remarks and Poster Prizes Announcement
|
| |
Prof. Dr. Med. K.R. Alexander Knuth
CEO and Medical Director
National Center for Cancer Care & Research
Chairman of Cancer Services
Hamad Medical Corporation
Doha, Qatar
|
